Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.05 USD
Change Today +0.17 / 2.16%
Volume 491.5K
LXRX On Other Exchanges
Symbol
Exchange
LXRX is not on other exchanges.
As of 7:40 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

lexicon pharmaceuticals inc (LXRX) Snapshot

Open
$7.92
Previous Close
$7.88
Day High
$8.10
Day Low
$7.92
52 Week High
07/9/14 - $12.46
52 Week Low
12/15/14 - $5.60
Market Cap
834.1M
Average Volume 10 Days
552.6K
EPS TTM
$-1.07
Shares Outstanding
103.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LEXICON PHARMACEUTICALS INC (LXRX)

Related News

No related news articles were found.

lexicon pharmaceuticals inc (LXRX) Related Businessweek News

No Related Businessweek News Found

lexicon pharmaceuticals inc (LXRX) Details

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs include telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome. The company’s drug development programs also comprise Sotagliflozin, an orally-delivered small molecule drug candidate that has completed Phase II clinical trials to treat type 1 diabetes; and has completed two Phase II clinical trials to treat type 2 diabetes, as well as for the treatment of type 2 diabetes in patients with renal impairment. In addition, it develops LX1033, an orally-delivered small molecule compound, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound that has completed Phase II clinical trials to treat autoimmune disease; and LX7101, a topically-delivered small molecule compound that has completed Phase I clinical trials for the treatment of glaucoma. Further, the company’s preclinical development programs comprise LX2761, an orally-delivered small molecule compound for the treatment of diabetes. It has license and collaboration agreement with Ipsen Pharma SAS; and drug discovery alliance with Bristol-Myers Squibb Company and Genentech, Inc. The company was founded in 1995 and is headquartered in The Woodlands, Texas.

106 Employees
Last Reported Date: 03/12/15
Founded in 1995

lexicon pharmaceuticals inc (LXRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $431.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $534.5K
Executive Vice President of CMC and Supply Op...
Total Annual Compensation: $457.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $445.4K
Compensation as of Fiscal Year 2014.

lexicon pharmaceuticals inc (LXRX) Key Developments

Lexicon Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 08:00 AM

Lexicon Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 08:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

Lexicon Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 08:40 AM

Lexicon Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 08:40 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Lonnel Coats, Chief Executive Officer, President and Director.

Lexicon Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Clinical Pipeline Update; Provides Financial Guidance for the Year 2015

Lexicon Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net loss of $28,076,000 or $0.04 per basic and diluted share compared to a net loss of $30,835,000 or $0.06 per basic and diluted share in the corresponding period in 2014. Total revenues were $1,792,000 compared to $277,000 reported a year ago. Loss from operations was $26,527,000 compared to $30,472,000 reported a year ago. The company revenue increased primarily due to revenues recognized from the license and collaboration agreement with Ipsen. The company completed enrollment in TELESTAR, its pivotal Phase 3 clinical trial of telotristat etiprate for patients with carcinoid syndrome. The company expects to announced top-line data from the TELESTAR trial in the third quarter of 2015. Telotristat etiprate is an inhibitor of tryptophan hydroxylase (TPH) that reduces peripheral serotonin production without affecting brain serotonin levels. The company will complete enrollment on April 30, 2015 in TELECAST, its companion study which is being conducted in order to obtain additional safety data. Lexicon has commenced enrollment of patients in the first of its two pivotal Phase 3 clinical trials of sotagliflozin for type 1 diabetes and is preparing to initiate screening in the second pivotal Phase 3 study. Sotagliflozin is a dual inhibitor of sodium-glucose transporters 1 and 2 (SGLT1 and SGLT2). In parallel with Phase 3 development, Lexicon is conducting a Phase 2 clinical trial of sotagliflozin in collaboration with JDRF focused on young adults with type 1 diabetes and high A1C, representative of a population of particularly high unmet need. The company expects contractual revenues from existing agreements in 2015 to be around $3 million. The company continue to expect its operating expenses in 2015 will be in the range of $130 million to $140 million. The company expects its net cash used in operations to be in the range of $150 million to $160 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LXRX:US $8.05 USD +0.17

LXRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.08 USD +0.07
Boston Scientific Corp $17.70 USD -0.11
CR Bard Inc $170.70 USD -0.24
Johnson & Johnson $97.46 USD -0.22
Medtronic PLC $74.10 USD +0.80
View Industry Companies
 

Industry Analysis

LXRX

Industry Average

Valuation LXRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 33.5x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LEXICON PHARMACEUTICALS INC, please visit www.lexpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.